Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2-Specific T Cells for Persistent Coronavirus...

Area of Science:

• Immunology
• Virology
• Infectious Diseases

Background:

• Persistent coronavirus disease 2019 (COVID-19) poses a challenge in immunocompromised individuals.
• Standard therapies may be insufficient for certain patient populations.

Purpose of the Study:

• To evaluate the safety and efficacy of viral-specific T cells (VSTs) in immunocompromised patients with persistent COVID-19.
• To characterize the clinical and virologic responses to VST administration.

Main Methods:

• Administration of VSTs under emergency investigational new drug applications to 6 immunocompromised patients.
• Clinical and virologic monitoring of patient responses.

Main Results:

• Three patients showed partial responses but ultimately did not survive.
• Two patients recovered, though the contribution of VSTs was confounded by concurrent antiviral treatments.
• One patient, refractory to remdesivir, achieved sustained recovery following VST administration.

Conclusions:

• VSTs represent a potential therapeutic option for persistent COVID-19 in immunocompromised patients.
• The role of VSTs in managing persistent COVID-19 warrants further investigation.
• Careful patient selection and further clinical trials are necessary to establish optimal use.